Overview

A Phase 2 Study to Evaluate the Efficacy and Safety of HS-20004 in Type 2 Diabetes Subjects.

Status:
Unknown status
Trial end date:
2020-01-15
Target enrollment:
Participant gender:
Summary
The study is being conducted to evaluate the efficacy and safety of Noiiglutide Injection as mono-therapy with different doses in subjects with type 2 diabetes compared to placebo for 16 weeks.
Phase:
Phase 2
Details
Lead Sponsor:
Jiangsu HengRui Medicine Co., Ltd.